HeartBeam Inc. (NASDAQ: BEAT) announced the completion of patient enrollment ahead of schedule in its ALIGN-ACS pilot study, which evaluates the HeartBeam System for heart attack detection. The study enrolled 120 patients presenting with chest pain at two clinical sites in Belgrade, Serbia. Participants were assessed using both a standard 12-lead ECG and HeartBeam's 3D ECG technology. Data analysis is currently underway, and the company plans to present the results at a major cardiology conference later this year.
The ALIGN-ACS pilot study is a critical step for HeartBeam as it seeks to expand the indication of its 3D ECG system beyond arrhythmia assessment to include heart attack detection. The company stated that the study results are expected to support discussions with the U.S. Food and Drug Administration (FDA) regarding the design of a planned pivotal trial in the United States and a future submission for expanded clearance. The HeartBeam System, which received FDA clearance for arrhythmia assessment in December 2024 and 12-lead ECG synthesis software clearance in December 2025, is the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a standard 12-lead ECG.
HeartBeam is also evaluating whether completing enrollment ahead of its previously anticipated third-quarter 2026 timeline could support a more accelerated regulatory pathway. The company holds over 20 issued patents related to its technology. The successful completion of enrollment ahead of schedule underscores the efficiency of the study design and the potential for faster market access. For more details, the full press release is available at https://ibn.fm/GEYtp.
The implications of this announcement are significant for both HeartBeam and the broader field of cardiac care. If the ALIGN-ACS study demonstrates the effectiveness of the HeartBeam System in detecting heart attacks, it could transform how acute cardiac events are diagnosed, particularly in remote or pre-hospital settings. The ability to collect 3D ECG signals from a portable, cable-free device could enable earlier detection and intervention, potentially improving patient outcomes and reducing healthcare costs. Furthermore, an accelerated regulatory pathway could bring this technology to market sooner, offering a new tool for physicians to identify cardiac health trends and acute conditions outside of medical facilities.
HeartBeam's progress also highlights the growing trend of miniaturized, patient-centric diagnostic devices. The company's platform technology is designed for portable use, allowing patients to be monitored wherever they are. This aligns with the shift toward decentralized healthcare and telemedicine, where continuous monitoring and rapid diagnosis are increasingly valued. The company's newsroom, accessible at https://ibn.fm/BEAT, provides the latest updates on BEAT.
